Optimized glucocorticoid therapy: teaching old drugs new tricks

Area of Science:

• Pharmacology
• Immunology
• Endocrinology

Background:

• Glucocorticoids (GCs) are vital for treating inflammatory and rheumatic diseases.
• Their effects are primarily mediated by genomic mechanisms involving the cytosolic glucocorticoid receptor (cGR), encompassing transactivation and transrepression.
• Rapid, non-genomic mechanisms also contribute to GC action, with potential clinical relevance via membrane-bound receptors, though underlying pathways require further elucidation.

Purpose of the Study:

• To explore the mechanisms of glucocorticoid action, focusing on both genomic and non-genomic pathways.
• To investigate the role of membrane-bound glucocorticoid receptors in rapid GC effects.
• To highlight ongoing efforts in developing improved glucocorticoid therapies with reduced adverse effects.

Main Methods:

• Review of existing literature on glucocorticoid receptor signaling pathways.
• Analysis of genomic (transactivation, transrepression) and non-genomic mechanisms of GC action.
• Discussion of clinical strategies and novel therapeutic developments for GC-induced side effects.

Main Results:

• Glucocorticoids (GCs) exhibit potent anti-inflammatory and immunosuppressive effects via genomic mechanisms.
• Non-genomic mechanisms, potentially involving membrane-bound receptors, contribute to rapid GC effects.
• Significant research is dedicated to mitigating GC-induced adverse effects and enhancing therapeutic outcomes.

Conclusions:

• Understanding both genomic and non-genomic glucocorticoid actions is crucial for optimizing anti-inflammatory therapies.
• Further research into non-genomic pathways, particularly those involving membrane receptors, is warranted.
• Development of innovative glucocorticoids and receptor ligands aims to improve the benefit/risk profile of GC treatment.